Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
2.
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood
; 139(6): 907-921, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601571
3.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
4.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Haematologica
; 108(10): 2626-2638, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078252
5.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Haematologica
; 108(9): 2331-2342, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951163
6.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
7.
Mechanistic basis and efficacy of targeting the ß-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Blood
; 135(15): 1255-1269, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068780
8.
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Haematologica
; 107(3): 690-701, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792219
9.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
10.
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Am J Hematol
; 97(12): 1599-1606, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117258
11.
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin ß-Like 1-ß-Catenin Protein Complex.
J Pharmacol Exp Ther
; 378(2): 77-86, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34006586
12.
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance.
Nat Immunol
; 10(1): 92-100, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19011628
13.
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Blood
; 134(1): 59-73, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023702
14.
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Blood
; 132(16): 1664-1674, 2018 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30185431
15.
Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes.
J Immunol
; 201(1): 124-133, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29752313
16.
Acute Disulfiram Poisoning in a Child: A Case Report and Review of Literature.
Indian J Crit Care Med
; 24(3): 203-205, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32435101
17.
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Am J Hematol
; 94(1): 74-79, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30328139
18.
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Am J Hematol
; 93(3): 401-407, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29218851
19.
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Cancer
; 123(16): 3050-3060, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28387922
20.
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Breast Cancer Res Treat
; 165(2): 375-382, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28623430